Andrew Madoff Dies of Mantle Cell Lymphoma

Andrew Madoff was the only surviving son of Bernie Madoff, whose notorious Ponzi scheme defrauded people of billions of dollars.

Photo credit: Peter Kramer, Getty Images

Andrew had been diagnosed with mantle cell lymphoma, and according to attorney Martin Flumenbaum, he died at Sloan Kettering Cancer Center, "peacefully, surrounded by his loving family."

Last year Andrew told People magazine that he blamed a recurrence of his lymphoma on the stress of his father's crimes.

Madoff's older son Mark committed suicide in 2010, on the second anniversary of his father's arrest. Currently his father is serving a 150 year prison term.

Both Andrew and Mark had always steadfastly denied knowledge of their father's Ponzi scheme. Officials never brought any charges against them.

In fact it was the two men who ended their father's scheme and turned him in.

Following Mark's suicide in 2010, officials did not allow his father to attend the funeral. The Federal Bureau of Prisons would not discuss Andrew's death and whether Bernie would be permitted to attend, but most believe he will not be.

Funeral arrangements are private. Andrew was 48 years old.

Source: CNBC

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap